← Back to Press Releases September 09, 2026 Interim Safety and Preliminary Efficacy of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome: Results from the POLARIS Phase 1/2 Program Share Post Email Copy Link Cell-Selective Targeting and Regulation The precision gene therapies being developed at Encoded are potentially capable of targeting specific cell types or levels of expression to address a range of disease mechanisms. Learn more Cell-Selective Targeting and Regulation The precision gene therapies being developed at Encoded are potentially capable of targeting specific cell types or levels of expression to address a range of disease mechanisms. Learn more
